Ceribell (CBLL) Q1 2026 earnings review
Strong Execution Masked by Soaring Legal and Commercial Costs
Ceribell delivered solid 29% revenue growth and raised its full-year guidance to $112-$116 million, fueled by strong account additions (up 33 sequentially). However, the path to profitability appears increasingly challenged in the near term. Operating expenses surged 36% to $43.9 million—outpacing revenue growth—driven heavily by the patent infringement lawsuit against Natus Medical and commercial headcount expansion. As a result, GAAP net loss expanded by 54% to $19.7 million. While gross margins remained resilient at 87% despite ongoing tariff headwinds, the lack of operating leverage and high cash burn rate require monitoring.
🐂 Bull Case
The successful commercial launch of neonate and pediatric products unlocks a new $400M market. A supportive CMS proposed rule for delirium NTAP reimbursement paves the way for a $1B 'greenfield' opportunity.
The land-and-expand strategy continues to deliver. Revenue grew 29% YoY, and the company added 33 active accounts in the quarter, reaching a total of 680.
🐻 Bear Case
Despite management's previous pledges to reach breakeven with cash on hand, operating expenses are accelerating (+36% YoY). Net loss deepened to $19.7M, pulling total cash and marketable securities down to $141.2M.
The Natus Medical patent infringement lawsuit is becoming a massive financial drag. IP litigation adjustments hit $5.6M in Q1 alone, draining capital that could otherwise support product innovation.
⚖️ Verdict: ⚪
Neutral. Top-line execution and product pipeline progress are excellent, but the staggering jump in operating expenses and litigation costs contradicts the narrative of a near-term path to profitability.
Key Themes
IP Litigation Decimating GAAP Profitability
The patent infringement suit initiated in July 2025 against Natus Medical is materially impacting the bottom line. Q1 2026 operating expenses spiked 36% YoY, with management explicitly citing legal enforcement costs. In Q1 2026, the IP litigation adjustment to EBITDA was $5.6M, a massive jump from $0.6M a year ago. This represents a significant cash drain that obscures the core business's performance.
Neonate, Pediatric & Delirium TAM Expansion
Ceribell is successfully transitioning from single-use seizure detection to a comprehensive brain monitoring platform. The commercial launch of neonate and pediatric products represents a major milestone following last year's pilots. Furthermore, a supportive CMS proposed rule for NTAP reimbursement for the delirium monitoring solution sets the stage for a major TAM unlock, with the final rule expected in August 2026.
Negative Operating Leverage
A primary bear thesis is playing out: revenue growth is decelerating slightly (from 42% in 25Q1 to 29% in 26Q1), while expense growth remains elevated (+36% YoY). Management previously stated they could reach cash flow breakeven with current cash, but a 54% expansion in Net Loss (to $19.7M) contradicts this positive narrative and raises questions about when the business model will finally scale.
Robust Account Additions Continue
The core land-and-expand strategy remains highly effective. Ceribell ended the quarter with 680 active accounts, implying a sequential addition of 33 accounts (up from 647 in 25Q4). This demonstrates stable execution of commercial investments made over the past year, proving that hospital demand remains inelastic.
Tariff and Macro Supply Chain Risks
While gross margin held up relatively well at 87% (down slightly from 88% a year ago), the company remains highly exposed to Chinese import tariffs. Management has previously guided that they are shifting some manufacturing to Vietnam, but any delays in this transition amid evolving geopolitical trade policies could compress margins later in the year.
High-Margin Subscription Revenue
Subscription revenue grew 29% YoY to $6.3M. This is a critical metric for the company because software subscriptions carry a near 97% gross margin and are completely immune to the hardware tariff pressures facing the physical EEG components.
Other KPIs
Stable. Continues to hover in the high 80s despite previously flagged concerns over China tariffs, indicating strong pricing power and successful early mitigation efforts.
Decelerating. Down from $159.3 million at the end of FY25. With a quarterly net loss approaching $20 million, the cash runway is tightening, increasing the pressure to rein in legal and G&A expenses.
Stable compared to -$10.9 million in 25Q1. This metric highlights that the explosion in GAAP Net Loss (-$19.7M) is almost entirely driven by non-core items like the Natus IP litigation and stock-based compensation.
Guidance
Accelerating vs prior guidance. Management raised the full-year target from the previously guided $111-$115 million. The midpoint ($114M) implies ~28% YoY growth. This reflects strong Q1 execution and likely bakes in initial modest contributions from the newly launched pediatric and neonate lines.
Key Questions
Operating Leverage Timing
With operating expenses growing 36%—faster than revenue this quarter—at what specific revenue run-rate do you expect to see meaningful operating leverage, excluding the noise of the Natus litigation?
Delirium NTAP Economics
With the supportive CMS proposed rule for delirium NTAP, how should we model the pricing and adoption curve for this indication once the final rule is published in August 2026?
Legal Spend Trajectory
IP litigation adjustments hit a massive $5.6M this quarter. Should we expect this run-rate of legal spend to persist through the remainder of 2026, or was Q1 unusually heavy due to the discovery phase?